Kent Chak-yu So MBChB , Jianqiang Xu MD , Kevin Ka-ho Kam MBChB , Shih-Hsien Sung MD , Krissada Meemook MD , Dee Dee Wang MD , Gilbert H.L. Tang MD, MSc, MBA , Alex Pui-wai Lee MBChB, MD , Yat-yin Lam MBBS
{"title":"Current Status of Tricuspid Valve Interventions in Asia Pacific Region","authors":"Kent Chak-yu So MBChB , Jianqiang Xu MD , Kevin Ka-ho Kam MBChB , Shih-Hsien Sung MD , Krissada Meemook MD , Dee Dee Wang MD , Gilbert H.L. Tang MD, MSc, MBA , Alex Pui-wai Lee MBChB, MD , Yat-yin Lam MBBS","doi":"10.1016/j.jacasi.2024.10.008","DOIUrl":null,"url":null,"abstract":"<div><div>Transcatheter tricuspid interventions are becoming increasingly more common in Asia Pacific. In the past decade, clinicians in Asia Pacific have worked with a multitude of new transcatheter tricuspid technologies. A standardized clinical algorithm to diagnose symptomatic tricuspid regurgitation to increase patient access to novel right heart therapies has not yet been identified. Anatomic diversity in the Asia Pacific patient population; disease prevalence patterns; and socioeconomic, cultural, and local health structures represent unique challenges in the treatment of these patients with right heart failure. As advancements are made in right heart failure and transcatheter tricuspid technologies, hopefully more patients can be treated not just in Asia Pacific, but across the entire world.</div></div>","PeriodicalId":73529,"journal":{"name":"JACC. Asia","volume":"5 3","pages":"Pages 405-423"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Asia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772374724004204","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Transcatheter tricuspid interventions are becoming increasingly more common in Asia Pacific. In the past decade, clinicians in Asia Pacific have worked with a multitude of new transcatheter tricuspid technologies. A standardized clinical algorithm to diagnose symptomatic tricuspid regurgitation to increase patient access to novel right heart therapies has not yet been identified. Anatomic diversity in the Asia Pacific patient population; disease prevalence patterns; and socioeconomic, cultural, and local health structures represent unique challenges in the treatment of these patients with right heart failure. As advancements are made in right heart failure and transcatheter tricuspid technologies, hopefully more patients can be treated not just in Asia Pacific, but across the entire world.